CAJ | 학술논문

同步放化疗使局部晚期非小细胞肺癌(NSCLC)的5年生存率由单纯放疗的5%提高到目前的15%左右,是目前标准治疗模式.应用三维适形放疗技术,采用常规分割方式和累及野照射,给予肿瘤较高的剂量,以及同步放化疗后进行巩固化疗显示出更好的疗效;诱导化疗的作用尚不确定;分子靶向药物有较好的应用前景.
동보방화료사국부만기비소세포폐암(NSCLC)적5년생존솔유단순방료적5%제고도목전적15%좌우,시목전표준치료모식.응용삼유괄형방료기술,채용상규분할방식화루급야조사,급여종류교고적제량,이급동보방화료후진행공고화료현시출경호적료효;유도화료적작용상불학정;분자파향약물유교호적응용전경.
The 5-year survival rate of patients with locally advanced non-small cell lung cancer has been raised to 15% from 5% by concurrent chemoradiotherapy(CRT)and CRT has been accepted as standard treatment for these patients.CRT using three-dimensional conformal radiotherapy technique,conventional fraction,and involved field irradiation followed by consolidation chemotherapy yields better outcome.The role of induction chemotherapy remains obscure.Target therapy strategy is promising.